RFP 2025.02 End-of-Grant Evaluation - Medicines Patent Pool (MPP III)

RFP 2025.02 End-of-Grant Evaluation - Medicines Patent Pool (MPP III)

In order to access the Request for Proposal (RFP) documents, please log-in as a registered Supplier (Account registration accessible on https://www.ungm.org/Account/Registration). If Bidders experience any difficulties in accessing the RFP documents after having registered and expressed interest, please send an email to: unitaid-rfp@who.int

Objective of the consultancy:

To identify a suitable provider with relevant experience to conduct an end-of-project evaluation on the MPP III investment on “Improving quality of life by expanding sustainable access to quality, appropriate, affordable, safe and effective essential medicines and technologies for HIV, TB, HCV and co-morbidities in LMICs.

Qualification of Firm and Consultants:

Bidders shall propose a multi-disciplinary team of 3-4 experienced evaluators, including the team leader. The team leader must have at least 10 years of experience leading evaluations of similar scope and complexity and a strong understanding of the pharmaceutical industry and licensing agreements and practices, particularly as related to the availability of medicines in LMICs. Core team members should have at least 5 years of individual experience in their respective areas of technical expertise.

The proposed evaluation team should meet the following requirements:

1. At least 5 years’ experience in conducting evaluations using mixed methods approaches, with at least one team member with expert level knowledge in collection and analysis of qualitative data; case study methodology and contribution analysis or other comparable evaluation approaches desirable

2. At least 5 years’ experience in, or familiarity with the business model of, the generic pharmaceutical industry, in particular, related to the development, production, and marketing/registration of medicines in LMICs;

3. Expert knowledge of licensing agreements and practices in the pharmaceutical sector; including technology transfer.

4. Knowledge of or familiarity with the challenges related to access to innovative medicines in LMICs desirable;

5. Demonstrable knowledge of or familiarity with the issues, sensitivities, and global debates on IPR and access to medicines in developing countries in general, and access to HIV, TB, and HCV medicines in particular;

6. Proficiency in English (knowledge of other UN languages an asset); final deliverables must be submitted in English; and

7. Include an appropriate representation with regard to sex, a broad mix of backgrounds, skills and perspectives, and national and international experience, including in resource-limited settings.

Bidders are invited to submit a proposal for the above mentioned RFP in accordance to the documents attached in the "Tender Document" tab. Proposals must be submitted via UNGM, through the “RFP documents” tab and upload documents in “My Tender Return” no later than 17h00 hours CET (Geneva time) on 10 February 2025 (extended tender closing date). 

Bid issuance date: 13-Jan-2025

Bid closing date: 10-Feb-2025 (extended closing date)